Beyondspring (NASDAQ:BYSI) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Beyondspring (NASDAQ:BYSI) from a hold rating to a buy rating in a research note released on Wednesday, Zacks.com reports. They currently have $23.00 price target on the stock.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

BYSI has been the topic of a number of other research reports. Maxim Group reiterated a buy rating and issued a $58.00 price target on shares of Brinker International in a research note on Tuesday, April 30th. HC Wainwright reiterated a buy rating and issued a $60.00 price target on shares of Beyondspring in a research note on Wednesday.



Shares of Beyondspring stock opened at $20.70 on Wednesday. The company has a market cap of $464.51 million, a PE ratio of -8.55 and a beta of 1.40. The stock has a 50-day moving average price of $19.20. Beyondspring has a 1 year low of $13.06 and a 1 year high of $26.98.

Beyondspring (NASDAQ:BYSI) last announced its quarterly earnings results on Wednesday, July 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.31. As a group, sell-side analysts forecast that Beyondspring will post -1.82 EPS for the current year.

About Beyondspring

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Read More: Do equity income investments outperform growth and income investments?

Get a free copy of the Zacks research report on Beyondspring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.